SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Cabergoline	Gonadorelin	Human Chorionic Gonadotropin (hCG)
Research Topic	Clinical / Endocrine Pharmacology	Reproductive Endocrinology	Reproductive Endocrinology
Pharmacology	Dopamine D2 receptor agonist medicine	Native-sequence gonadotropin-releasing hormone (GnRH)	Placental glycoprotein hormone and LH/hCG-receptor agonist gonadotropin
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade BStrong controlled human evidence	Grade AStrong regulatory + clinical evidence
Evidence boundary	Cabergoline is classified here as Dopamine D2 receptor agonist medicine. Prescription evidence applies to hyperprolactinaemic disorders with clinical monitoring. FDA-authorised prescription products exist for defined hyperprolactinaemic disorders; exact supplier tablets are not verified. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	A native-sequence GnRH peptide with historical, bounded U.S. human approvals; discontinued human products, current veterinary labels and unapproved online products must not be conflated.	A placental glycoprotein hormone with product-specific prescription uses in reproductive medicine and selected endocrine contexts. Urine-derived Pregnyl, recombinant Ovidrel, endogenous hCG and online weight-loss products are not interchangeable; hCG is not FDA-approved for weight loss.
Unknowns	Insufficient data in the current dataset	English translation is not yet verified for 5 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ตัวตน ความแรง ความบริสุทธิ์ และความปราศจากเชื้อของสินค้าที่ใช้ชื่อ gonadorelin นอกห่วงโซ่ยาที่อนุมัติ ผลลัพธ์ระยะยาวเมื่อใช้ในประชากรหรือเป้าหมายนอกข้อบ่งใช้ประวัติศาสตร์ ความเทียบเท่าระหว่าง gonadorelin hydrochloride, acetate และผลิตภัณฑ์ที่ไม่ระบุรูปเกลือ สถานะผลิตภัณฑ์มนุษย์ปัจจุบันในแต่ละประเทศเมื่อไม่มีเลขทะเบียนที่ตรวจสอบได้ ความเสี่ยงเฉพาะบุคคลเมื่อมีโรคต่อมใต้สมอง โรคฮอร์โมน ภาวะเจริญพันธุ์ หรือยาร่วม	Insufficient data in the current dataset
Limitations	Cabergoline molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) หลักฐานรักษาหลักมาจากงานขนาดเล็กในทศวรรษ 1980–1990 หลายงานเป็น open-label หรือใช้ historical controls และผลิตภัณฑ์ Lutrepulse ถูกยุติด้วยเหตุผลเชิงพาณิชย์กับข้อจำกัดของ pump ประวัติการอนุมัติไม่เท่ากับการมีผลิตภัณฑ์มนุษย์ที่วางตลาดปัจจุบัน และ animal-drug approval ไม่สามารถถ่ายโอนสู่คน	Insufficient data in the current dataset
Sources	DailyMed · Cabergoline human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=17086 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021322s000_Luveris_medr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020517_s002ap.pdf https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1451663c-b85a-4b45-8b27-6d572d0032f9 https://pubmed.ncbi.nlm.nih.gov/1743321/ https://precision.fda.gov/ginas/app/ui/substances/80386332-c028-4b4a-b470-6a4ae635d713 https://www.ema.europa.eu/en/medicines/veterinary/mrl/gonadotrophin-releasing-hormone-maximum-residue-limit https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx https://products.mhra.gov.uk/	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e94155f-19be-4944-b197-be4edbb4faf9 https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a683e58a-63ea-44b8-a326-1a99a537bcf2 https://www.fda.gov/consumers/consumer-updates/avoid-dangerous-hcg-diet-products https://purplebooksearch.fda.gov/index.cfm?blaNo=017692&event=productdetails https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.